CAL-51 Xenograft Model Service for Breast Cancer

The CAL-51 xenograft model stands as a sophisticated in vivo platform for investigating the molecular drivers of triple-negative breast cancer (TNBC), providing a high-fidelity environment to evaluate the efficacy of next-generation therapeutic candidates. Alfa Cytology offers an industry-leading CAL-51 xenograft model service, leveraging our extensive expertise in oncology research to deliver precise, reproducible data that streamlines your path to clinical trials.

Overview of CAL-51 Xenograft Model for Breast Cancer

The CAL-51 cell line is a human breast cancer model derived from a pleural effusion of a patient with metastatic disease. It is classified as a triple-negative breast cancer (TNBC) subtype, characterized by the lack of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) expression.

In vivo, the CAL-51 model is known for its remarkable genetic stability and high tumorigenicity in immunocompromised mice. One of the distinguishing features of CAL-51 is its PIK3CA mutation and specific metabolic profile, which allows researchers to study PI3K/AKT/mTOR signaling pathways and targeted inhibition strategies.

Cell Line Information: CAL-51

The CAL-51 cell line maintains a consistent epithelial morphology and exhibits aggressive growth characteristics both in vitro and in vivo.

At Alfa Cytology, we prioritize the scientific integrity of every project by employing rigorous quality control measures, including STR profiling and mycoplasma testing for all cell lines. Our specialized technical team is an expert in the delicate procedures required for in vivo model establishment, ensuring that the CAL-51 tumors precisely reflect the biological complexity of human breast cancer for your therapeutic evaluations.

Our Services

Workflow of CAL-51 Xenograft Model Construction

Alfa Cytology follows a meticulously standardized workflow to ensure the successful construction of the CAL-51 xenograft model:

• Cell Preparation & Quality Control: CAL-51 cells are expanded in vitro under optimal conditions. Cells are harvested during the logarithmic growth phase and undergo rigorous QC to confirm viability and phenotype.
• Host Selection: Healthy, standardized immunocompromised mice (such as Athymic Nude or SCID mice) are selected and allowed to acclimate to our facility environments.
• Surgical Inoculation: A precise concentration of CAL-51 cells, typically prepared with a matrix carrier to enhance initial engraftment, is injected in vivo via subcutaneous or orthotopic routes.
• Growth Monitoring: Following inoculation, animals are monitored daily for health status. Tumor volumes and body weights are recorded regularly using calibrated instruments to track growth kinetics.
• Study Initiation: Once tumors reach a pre-defined, statistically relevant volume, mice are randomized into treatment and control groups to begin therapeutic dosing.

Fig 1. CAL-51 Xenograft Model Construction Workflow

Case Study - CAL-51 Xenograft Model Development

In a recent validation study conducted at Alfa Cytology, the CAL-51 xenograft model was utilized to assess the synergistic effects of a novel PI3K inhibitor combined with standard chemotherapy. The model demonstrated exceptional tumor take rates and highly uniform growth kinetics across all study cohorts, ensuring high statistical power for the efficacy evaluation. The in vivo results clearly demonstrated a significant reduction in tumor burden in the combination group compared to monotherapy, providing the client with robust and reproducible proof-of-concept data essential for their regulatory submission.

Why Choose Alfa Cytology?

• Targeted Expertise: Specialized knowledge in TNBC and PIK3CA-mutant signaling models.
• Technical Precision: Proven inoculation techniques that ensure high take rates and reproducible growth.
• Comprehensive Readouts: Capability to perform integrated PK/PD analysis and endpoint histological evaluations.
• Commitment to Quality: All studies are conducted in modern facilities with strict adherence to ethical and scientific standards.

Contact Us

Ready to accelerate your breast cancer research with a high-performance CAL-51 xenograft model? Our team of oncology specialists is available to provide tailored experimental designs and technical support for your drug discovery milestones. Please reach out to us today to discuss your project requirements, or contact us directly to request a comprehensive quote from Alfa Cytology.

For research use only. Not intended for any clinical use.